TiumBio Reports Q1 2026 Operating Loss of KRW 4.5B; Positive Clinical Progress in Key Pipelines

Revenue: KRW 2.95B (YoY +40%), Operating loss: KRW 4.54B (improved from KRW 5.35B)
TU2218 (Tosposertib): Phase 2a HNSCC interim DCR 82.4% (SITC 2025); BTC cohort dosing ongoing
TU2670 (Merigolix): EU Phase 2a for endometriosis met primary endpoint; domestic Phase 2 for uterine fibroids positive topline
TU7710 (Hemophilia): EU Phase 1b ongoing; up to 7x half-life extension confirmed
Cash & equivalents: KRW 3.38B + short-term financial assets: KRW 4.0B = total liquidity KRW 7.38B
Debt ratio: 182.14% (FY2025 end: 161.11%)
Consolidated net loss: KRW 5.41B (EPS: -KRW 186)